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Abstract
The immune system is engaged in a constant antigenic surveillance through the Major Histocompatibility Complex (MHC)
class I antigen presentation pathway. This is an efficient mechanism for detection of intracellular infections, especially viral
ones. In this work we describe conformational patterns shared by epitopes presented by a given MHC allele and use these
features to develop a docking approach that simulates the peptide loading into the MHC cleft. Our strategy, to construct in
silico MHC:peptide complexes, was successfully tested by reproducing four different crystal structures of MHC-I molecules
available at the Protein Data Bank (PDB). An in silico study of cross-reactivity potential was also performed between the wild-
type complex HLA-A2-NS31073 and nine MHC:peptide complexes presenting alanine exchange peptides. This indicates that
structural similarities among the complexes can give us important clues about cross reactivity. The approach used in this
work allows the selection of epitopes with potential to induce cross-reactive immune responses, providing useful tools for
studies in autoimmunity and to the development of more comprehensive vaccines.
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Introduction
Cytotoxic T Lymphocytes (CTLs) recognize processed peptides
presented in the context of the Major Histocompatibility Complex
(MHC) class I, on the surface of nucleated cells [1]. The presented
peptides, or epitopes, are short sequences with eight to twelve
amino acids in length. These epitopes are derived from proteins
endogenous to the cell and could derive from the cell itself or from
intracellular parasites, making this pathway an important
mechanism for antiviral defense [2]. The interaction between a
T Cell Receptor (TCR) and the MHC:peptide complex (pMHC) is
degenerated. It has been proposed that one single TCR can
recognize up to 10
6 different pMHCs [3]. This capacity of one
TCR to recognize different epitopes defines the phenomenon of
cross-reactivity [4].
The term ‘‘heterologous immunity’’ is used to describe a partial
immunity induced against a pathogen through the host immunization
with a non-related pathogen or antigen. This phenomenon, directly
related to the mechanism of cross-reactivity, depends on the
immunological history of the host and, consequently, on memory
lymphocytes. Heterologous immunity can be involved in situations as
diverse as pathogen clearance, chronic viral infection or autoimmunity
induction [5]. There are several reports of heterologous immunity
among non-related viruses and also reports on autoimmunity induced
by molecular mimicry [6,7,8], but the mechanisms that establish such
cross-reactions have not been completely solved [4]. Most studies on
cross-reactivity are focused on very similar epitopes that share almost
all amino acids [9]. However, cross-reactivity in vitro was already
observed between epitopes that share less than 40% of their linear
amino acid sequences [10]. Therefore, we need to look beyond the
linear amino acid sequences to study or predict cross recognition
between peptides. It is important to evaluate structural and chemical
features such as amino acids physicochemical characteristics of the
peptide [11], topology and electrostatic potential of the MHC:peptide
complex [7,8].
The HLA-A2-restricted NS31073 epitope (CI/VNGVCWTV) is
one of the main targets of the CTL response against Hepatitis C
Virus (HCV) and has been also reported in cross-reactivity events
[9,12,13]. In a work published in 2008, Fytili and colleagues
investigated the relevance of each amino acid position of this
epitope, for T cell recognition [13]. They tested alanine exchange
peptides against NS31073-specific CD8+ T cells and found that
even single amino acid changes could almost completely abolish
the production of interferon-a ˜ by wild-type-specific T cells.
Molecular docking, as a bioinformatic tool, has been success-
fully used to both perform the complexation between a ligand and
its receptor as well as to explore possible sites of interaction
between a given compound and one protein of interest [14]. There
have been several works describing the use of molecular docking in
drug design, not only contributing to a better understanding of the
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to the development of new ones [15]. To refine the models
generated by docking, an approach based on Energy Minimiza-
tion (EM) can be used. This technique, normally performed in
aqueous solution, induces the protein and its ligand to adopt a
more stable conformation, closer to in vivo state [16,17].
In the present work we performed a full search of the MHC
structures available at the PDB, and identified conformational
patterns shared by epitopes presented by a given allele. Besides an
immunologically interesting finding, these features allow us to
construct pMHC complexes with any peptide of interest. For
instance, through the combined use of molecular docking and EM,
we built the structure of the NS31073 epitope in the context of the
HLA-A*0201 allele (HLA-A2-NS31073), aiming to identify the
existence of molecular characteristics which may be involved in
the stimulation of immune response. The strategy used to build
this complex, followed by the use of softwares that enabled us to
analyze structural and chemical features of the generated
complexes, allowed us to study new pMHCs under the TCR
‘‘point of view’’, and therefore, to infer a cross-reactive potential
between two different epitopes [7,8,18]. In this context, peptide
targets could be further synthesized for in vitro confirmation of their
immunogenicity and cross-reactive potential against other targets
of interest, such as immunodominant epitopes of related viruses.
Once confirmed these features of interest, these targets could be
used in polytope DNA vaccines, especially for heterologous prime-
boost approaches [19,20,21,22].
Results and Discussion
Identification of an allele specific structural epitope
pattern
We have performed a search for all MHC-I structures deposited
at PDB and have analyzed the conformation of different epitopes
presented by these MHC molecules. A conformational pattern,
specific for each allele, has been observed, evidencing that the
tridimensional structure of the presented epitope is not solely an
intrinsic characteristic of the epitope itself (i.e. due to the amino
acid sequence per se), but is actively determined by the MHC-I
cleft, which varies according to the MHC allele (Figures 1 and 2).
The structural data of the epitopes capable to bind to the H-2D
b
and H-2K
b molecules (the murine MHC alleles with the highest
number of structures at the PDB) were analyzed taking into
consideration both their anchor positions as well as the cleft
structure. The results indicated the regions of the epitope that
suffer a restraint and those that could accept variations in the
amino acid side chains. We postulate that more restrained regions
were related to the MHC binding although regions more
‘‘flexible’’ and exposed would contact with the TCR, therefore
defining the pMHC specificity (Figure S1).
Although the sequence of some of the epitopes included in this
analysis differs by just one amino acid, what could bias the
identification of a general pattern of an allele, epitopes with far
different sequences maintained the same pattern. Moreover,
variants of the same epitopes were included based on the idea that
the exchange of any amino acid can induce an alteration in the
backbone torsions and even abrogate the recognition by a TCR
[13,23]. When analyzing the structures, we verified that exceptions
to the pattern occur as a requirement needed to accommodate
longer sequences on the MHC cleft. We also realized that structural
patterns are specific for a given MHC allele, so that epitopes
presented by different alleles shows different conformations
(Figure 1A). Furthermore, previous works already indicated that a
same epitope will adopt different conformations when presented by
different MHC alleles (Figure 1C) [24]. Together, these data
indicate that the epitope conformation in the MHC cleft is
determined both by its linear sequence and the cleft topology.
Figure 1. Superposition of H-2D
b-H-2K
b -restricted epitopes.
Structures of five H-2D
b -restricted epitopes (1CE6, 1S7V, 1WBZ, 1ZHB
and 3BUY) and of five H-2K
b-restricted epitopes (1FO0, 1FZJ, 1LK2, 1RJY
and 1S7R) were superposed. The color pattern was kept on figures A, B
and C. A: The side view shows the conformational differences among the
H-2D
b (red) andthe H-2K
b –restricted epitopes (blue), especially between
positions 5 and 7 (p5-7). B: Top view of the 10 superposed peptides. C:
Two crystal structures (1S7V and 1S7R) representing the same epitope
(KAVYNLATM) in the context of these two different alleles.
doi:10.1371/journal.pone.0010353.g001
Figure 2. Conformational pattern of H-2D
b-restricted epitopes.
A: Crystal structures of 28 epitopes (Table 1) - size range between 8 and
11 amino acids - were superposed. It is possible to observe the existence
of a shared pattern among the epitopes main chains (backbone). The
orientation (N-terminal to C-terminal) was kept. B: Top view of the same
28 epitopes. C: Only the epitopes with nine amino acids were
superposed, showing that the variability among the epitopes structure
is determined by differences in length. The side chains of the epitopes
were not represented in these images, and an amino acid (p7) of epitope
2VE6 (altered photocleavable peptide) was excluded.
doi:10.1371/journal.pone.0010353.g002
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adopt an adequate conformation and to do so, some features
specific for each MHC allele are required. Most of these features
had already been discussed in literature, but they have not as yet
been directly related to conformational patterns of the presented
epitopes. For instance, the differences between peptides restricted
to H2-D
b and H2-K
b can be partially explained based on the
pattern of hydrogen bounds generated between the peptide and
the MHC molecule in each allele [25] and the presence of a
tryptophan residue (Trp73), in the D
b molecule [26] (Figure 3).
The Alpha-2 domain (a2) of MHC-I molecules is constituted by
two segments of a-helix joined by a little loop that protrudes from
the cleft. We verified that in most cases the peptide backbone
follows the a2 structure, having a bulge at the C-terminal, in the
same region of the bulged coil. Part of this bulge is probably
induced by the presence of a tryptophan residue (Trp147) in the
a2 domain that is highly conserved in several MHC alleles. H2-
D
b-restricted epitopes have an even higher bulge at C term (p6-8)
because this allele has a second tryptophan residue (Trp73), in the
same region, but from the a1 domain. These two residues almost
close the cleft, forcing the peptide to pass above them (Figure S2).
An alignment of all entire sequences of H2-D
b, H2-K
b and HLA-
A*0201 available at PDB, has revealed the presence of the
Trp147 in all sequences of these alleles. All the sequences of H2-
D
b also have the Trp73 residue. The H2-K
b sequences have
serine in position 73 of a chain. The absence of the tryptophan
results in a deeper cleft in this region. Besides, we verified that in
some cases (e.g. 1LK2) the serine residue at this site also
establishes an hydrogen bound with the epitope at p5, that is one
of the anchor positions of the H2-K
b epitopes (data not shown).
In the HLA-A*0201 allele, the residue at position 73 is a
threonine (Thr73) and does not seem to be involved in any
hydrogen bond with the epitope. However, this allele has another
highly conserved residue (Asp77) that establishes H bonds with
the epitope C-terminal.
A main conformation for the backbone residues of the 9-mer
peptides restricted to the human allele HLA-A*0201 was also
identified in our work (Figure S3), although when compared to
murine described patterns, a greater divergence was observed.
Interestingly, most of the divergent peptides are cancer related
and, as already discussed in the literature, cancer related peptides
present great conformational variation [27]. Deviation of the
allele-specific pattern may not prevent the presentation on this
allele, but might interfere either in the stability of the complex or
in CTL stimulation. According to that, there is at least one
example of deviation from the pattern and reduction of TCR
recognition. Buslepp and colleagues published a paper on the
crystal structures of three HLA-A2:peptide complexes [28]. One of
them was an agonist (1I7U) of the TCR and the others were
described as null (1I7T) and antagonist peptides (1I7R). These
structures were herein superposed to other 31 HLA-A*0201-
restricted peptides and the agonist fit exactly with the described
pattern, while the other two peptides deviate from this pattern
(Figure S3).
We also looked for these conformational patterns in B*0801,
B*2705 and B*35 (Figure S3 and Table S1). We believe that the
existence of patterns could be extrapolated to other alleles, even
those of other species. However, this cannot be demonstrated now,
since the number of non-human/non-murine MHC-I structures
available is a very small.
Figure 3. Interactions between epitope and MHC cleft. A: Images of H-2D
b (1CE6) and H-2K
b (1RJY) complexes are generated with Chimera
package. Position of the complexes is indicated in the Side View Window (A1,B1,C1,D1). H-2D
b-restricted peptide is depicted in red (A, B) and H-2K
b-
restricted peptide is depicted in blue (C,D). MHC side chains that interact with the peptide are represented as sticks and Hydrogen bonds are
represented as light blue lines. The MHC Alpha-1 domain (a1) and the first position of the peptide (p1) are indicated, as also some amino acid labels.
doi:10.1371/journal.pone.0010353.g003
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backbone of the peptide, this does not imply a random distribution
of the side chains along the cleft. In fact, a more detailed study of
the 28 H2-D
b ligands (Table 1) evidenced the existence of regions
with different degrees of restriction over the amino acids side
chains. Epitopes in the H2-D
b cleft are positioned in such a way
that a portion of its amino terminal (N-terminal) end is hidden
under the MHC side chains (p2–3 of the epitope) while another
portion (p6–7) is out of the MHC cleft (Figure S1A). Not
surprisingly, there is higher identity among side chains of different
epitopes in p2–3 and higher diversity in p6–7 (Figure S1B). The
p6–7 region, where the side chains are more diverse among
different epitopes, will contact the TCR and therefore will
determine the TCR specificity. We also observed low diversity
among side chains in positions p5 and p9, described as the anchor
positions of this allele. An alignment of the 28 H-2D
b ligand
sequences, considering its physicochemical characteristics, indi-
cated a preferential occurrence of an asparagine on the fifth
position, although in three cases (1INQ, 1JUF and 1BZ9) a
nonpolar amino acid occupied this position. Most of the H-2D
b
ligands had nine amino acids; however, we also found 10-mers and
11-mers. The last position (p9, p10 or p11) was also conserved.
Almost all sequences presented nonpolar amino acids at this site,
except for one epitope, which had a cysteine (1FG2). Despite the
differences in length, the anchor positions (p5 and the last amino
acid) were conserved and length adjustments occurred at p6–7,
with foldings outside the cleft. At this region a higher divergence
could be observed, even in the backbone itself (Figures 2A and
2C). One of the ligands, the synthetic peptide FAPGVFPYM
(1BZ9), highly deviates from the backbone pattern, especially at
p5, rising up out of the cleft (Figure S4). This epitope does not
possess the canonical anchor residue at p5 and, as briefly discussed
in the original reference, peptides may occasionally bind without
primary anchor residues if other residues within the peptide
compensate the lost binding energy [29]. This could account for its
unusual shape, although it is important to stress the fact that this is
a synthetic peptide.
The H-2K
b ligands analyses also demonstrated a conservation
of the side chains in amino acids presented at anchor positions. Of
the 21 analyzed sequences (Table S2), 16 have aromatic amino
Table 1. List of H-2D
b ligands available at PDB.
PDB code Epitope description Sequence (aa) Nu of aa
1FG2* LCMV Peptidic Epitope (gp33) LAVYNFATC 9
1JPF* LCMV Peptidic Epitope (gp276) SGVENPGGYCL 11
1JPG* LCMV Peptidic Epitope (np396) FQPQNGQFI 9
1INQ* MHC Class I H13
a minor histocompatibility peptide SSVVGVWYL 9
1JUF* Minor Histocompatibility Antigen peptide (H13
b) P4(Val/Ile) SSVIGVWYL 9
1N3N* Mycobacterial hsp60 epitope SALQNAASIA 10
1QLF* Sendai NP324-332 (gly327 replaced by o-glcnac serine) FAPSNYPAL 9
1S7U/2F74/ 1FFN/1N5A* LCMV-derived immunodominant peptide (gp33) KAVYNFATM 9
1S7V* LCMV-derived (gp33) index peptide - escape variants KAVYNLATM 9
1S7W* LCMV-derived (gp33) index peptide - escape variants KALYNFATM 9
1S7X* LCMV-derived (gp33) index peptide - escape variants KAVFNFATM 9
1FFO* Gp33 syntethic peptide with substitution K1A /C9M AAVYNFATM 9
1FFP* Gp33 syntethic peptide with substitution K1S /C9M SAVYNFATM 9
1WBX* Peptide from Influenza A (pr8) HA468-477 SQLKNNAKEI 10
1WBY/1YN6* Peptide from Influenza A (pr8) PA224-233 SSLENFRAYV 10
1YN7* Mutated peptide (R7A) from RNA polymerase subunit P2 SSLENFAAYV 10
1ZHB* 9-mer peptide from Dopamine beta-monooxygenase KALYNYAPI 9
1BZ9* Synthetic Peptide (P1027) FAPGVFPYM 9
1CE6* Sendai Virus Nucleoprotein Peptide (NP324-332) FAPGNYPAL 9
2VE6* Altered peptide of Sendai virus (Photocleavable peptide) FAPGNYPAL 9
2CII Sendai virus nucleoprotein epitope FAPGNYPAL 9
2ZOK* 9-meric peptide from Spike glycoprotein ASLWNGPHL 9
2ZOL* 9-meric peptide from Spike glycoprotein - Mutation: W4S ASLSNGPHL 9
1HOC* Influenza virus peptide NP366-374 ASNENMETM 9
3CPL* Influenza virus peptide NP366-374 with substitution M6A ASNENAETM 9
3BUY* Epitope of PB1-F2 LSLRNPILV 9
3CC5* Nonameric peptide from Melanocyte protein Pmel 17 KVPRNQDWL 9
3CCH* nonameric peptide murine gp100 EGSRNQDWL 9
3CH1* nonameric peptide chimeric gp100 EGPRNQDWL 9
Thirty-three files containing H-2D
b alleles were found in PDB, 28 (*) presented different epitopes. These 28 epitopes were used at structure and sequence analyses. 1FFO
presents an MHC interacting with the TCR. Since this interaction could affect the conformation of the epitope, this structure was excluded. Structures presenting
incomplete epitope sequence have been also excluded (e.g. 2CII). 1BZ9 epitope was included in all analyses, however it was excluded in Figure 1 and Figure 1SB.
doi:10.1371/journal.pone.0010353.t001
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presented polar amino acids (N, S or T) at this position. The
epitope from 1WBZ was the only one with a positively charged
amino acid at p5, but this epitope presents a non-canonical
binding motif which may have some influence over the
immunodominance [26]. All sequences had a nonpolar amino
acid at the last position (C-term). In comparison to the H-2D
b
allele, H-2K
b seems to be less restrictive to peptide ligands,
allowing a greater divergence even at p4 (Figure S5).
Establishment of a strategy to build pMHC compIexes
Considering that the backbone structure of the epitope is shaped
by its direct interaction with the MHC cleft, we can postulate that
epitopes capable to be presented by a given MHC allele will adopt
rather similar conformational structures to other peptides
presented by the same allele. This has been the premise for
developing a new approach that allows us to build pMHCs whose
crystal structures were unavailable. In this approach, we use a set
of epitopes — already determined by crystallography in the cleft of
the MHC-I of interest — to choose a standard epitope structure.
Thereafter, this standard is being used as a template to build the
structure of another epitope (see methods).
This strategy has been used to reproduce the crystal structure of
four different pMHCs available at PDB (Table 2). For instance, we
reproduced the HLA-A2-P17 complex, PDB access number
2V2W, using as template a different HLA-A2-restricted epitope
(SL9-1A/6A/8A)[13]. The structures have been fit by MHC C
a
atoms and a Root Mean Square Deviation (RMSD) value of
0.96 A ˚ (for all epitope atoms) was obtained. This value accounts
not only for the torsional differences between the reproduced
epitope and the crystal, but also for differences in epitope position
inside the cleft. According to the literature, RMSDs lower than
2.2 A ˚ are considered valid reproductions [30,31]. In order to
assure the reproducibility of the used approach, we also
reproduced the entire set of available class I PDB structures for
the alleles with established peptide pattern. We were able to
reproduce a total of 46 structures —11 HLA-A*0201, 19 H2-D
b
and H2-K
b — with RMSD values of 1.75460.4675 A ˚ (all peptide
atoms), which characterizes a high fidelity reconstruction index.
Exceptions to the predicted pattern, as previously discussed, were
not reproduced.
Considering that the proposed approach successfully repro-
duced a large set of structures from three different MHC-I alleles,
and also reproduced the structure of epitopes with different lengths
inside the cleft of the same allele (H2-D
b), we can use this
computational strategy to built pMHC complexes based on the
linear amino acids sequence of any epitope. It should be noted that
not all peptides can be presented by a given MHC allele. We
believe that the docking process can identify ‘‘bad ligands’’
through the variation of the binding energy. However, this
approach becomes more reliable if preceded by an analyses of
epitope prediction or, at least, by the verification of the affinity
between the epitope and the MHC of interest, through the use of a
MHC ligands databank.
Several works focused on MHC Class-I binding peptide
prediction [32,33,34,35,36,37] and it is important to emphasize
that this is not the aim of our approach. The allele-specific patterns
and the combined use of Docking and Energy Minimization (D1-
EM-D2) are presented here as a tool to construct new pMHC
complexes, which can be further analyzed using several available
programs. There are few alternative methodologies to construct
pMHC complexes, and they present several limitations regarding
the MHC alleles or the epitope length [37,38,39,40]. Although it
has its own limitations, our approach can be applied to different
epitope lengths and MHC alleles, being also more reliable, as it
uses an established conformational pattern for each allele as
template for the peptide. Therefore, the realistic prediction of
pMHC complexes remains an important goal in peptide vaccine
design and here we describe a new approach that will certainly
contribute to this field.
In silico study of cross-reactivity potential between the
wild-type complex HLA-A2-NS31073 and nine pMHCs
presenting one amino acid changed by alanine
In order to analyze cross reactive potential, Fytili et al. 2008
[13] tested in vitro the T cell stimulation capacity of an HCV wild-
type epitope NS31073 (CINGVCWTV) and nine other epitopes
derived from this original, each one being an alanine exchange
variant, against a cell population previously exposed to the original
epitope. In our work, the presently described docking approach
was used to built the pMHC complexes of the HCV wild-type
epitope NS31073 (CINGVCWTV) and the nine other epitopes in
the context of the human allele HLA-A*0201, aiming at analyzing
structural and chemical features of these complexes. The
accessible surface area (ASA) of the peptides in the cleft was also
calculated, and interesting results came out. The plot of these
values for each residue has presented quite identical signatures
among the peptides that induced strong response in vitro (Figure
S6). Some works have associated high ASA values and peptide
immunodominance [26]. This relation was not seen in our study,
whereas some epitopes with poor response, in vitro, presented high
values of ASA, especially at p5. However, it is important to note
that the peptide with the lowest value of ASA at p5 (Seq3) was the
only peptide that does not stimulate a detectable response [13]. In
Table 2. Reproduction of pMHC crystal structures.
Allele Ep. Length Target MHC donor Pattern Template BE D1
a (Kcal/mol) BE D2
b (Kcal/mol) RMSD
c RMSD
d
H2-D
b 9 1HOC 1WBX 1JPG 211,2 212 1,22 1,48
H2-D
b 10 1WBX 1WBX 1WBY 211,2 212,3 1,49 1,53
H2-K
b 8 1LK2 1LK2 1RJY 211,8 213,6 1,28 1,45
HLA-A*0201 9 2V2W 2V2W 1T1Z 212,3 212,9 0,89 0,96
Four different pMHC crystal structures available at PDB were reproduced. A docking approach based in the allele-specific patterns was performed (see methods).
Information about the MHC alleles, the PDB files and the results are presented in this table.
a Binding Energy of the first docking.
b Binding Energy of the second docking.
c Root Mean Square Deviation for all epitope atoms. Calculated after fit the epitopes by C alpha.
d Root Mean Square Deviation for all epitope atoms. Calculated after fit the MHCs by C alpha.
doi:10.1371/journal.pone.0010353.t002
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value, we also performed the construction and analysis of 28
pMHC complexes, from 6 different HCV genotypes, described by
Fytili et al. 2008. In their description, the experimental data
showed a cross-genotype-reactivity, particularly between the wild
type peptide (Peptide 1 from Genotype 1 or G1_1) and the
peptides from genotype 6 (G6_23 to G6_28). In agreement with
this data, the ASA values from genotype 6 presented the same
pattern of the wild type peptide (Figure S7) and the peptides with
higher deviation from this ‘‘ASA pattern’’ (G3_16, G3_18 and
G3_20), presented the lowest levels of IFN-c production in all
ELISPOT assays (Fytili et al. 2008). However, it is also important
to note that some peptides with low response in vitro presented
ASA values quite similar to the wild type. These results support the
idea that large deviations in ASA values may indicate a poor
stimulation in vitro, but the opposite is not true. Therefore, the
ASA values are just an indicator that may be taken into account
during a screening for possible targets, and cannot alone explain
all variation observed in vitro.
A previous work have already determined the importance of the
epitope central amino acids for the T cell recognition [5]. As
described by Fytili et al. 2008 [13], alanine exchanges at p3, p4, p5
and p7 strongly affected T cell stimulation capacity. However, the
peptide with the C6A exchange stimulated T cells at similar levels
as compared to the wild-type epitope. This is an important change
in terms of physicochemical characteristics and is quite curious
that this does not seem to affect T cell recognition. We have
analyzed the TCR-interacting surfaces of all complexes concern-
ing their topology and electrostatic potentials. The results
indicated that this C6A substitution has almost no effect in the
pMHC interacting surface (Figure 4J). In agreement with the
similar ASA values, the complexes 8, 9 and 10 presented quite
identical topologies and charge distribution. We therefore
postulate that this similarity is the main aspect responsible for
the described cross recognition of these complexes by the
CVNGVCWTV-specific CD8+ T cells [13].
Using the same dataset, the pMHC surfaces can also provide
information about the peptides that poorly stimulate the
production of interferon-a ˜. For instance, the peptide number 5
(CIAGVCWTV) was the only out of ten peptides, in which the
tryptophan indole ring had turned to the C terminus end of the
peptide. This change of position caused not only a difference of
topology but also a reduction of a positively charged area at the
pMHC surface (Figure 4G). To ascertain that this observation was
not spurious, the steps to construct this complex were repeated
using a higher value of exhaustiveness (=15) at AutoDock Vina
program [31]. As discussed before, complex 3 presented the lowest
ASA value at p5, and this value reflects the existence of a less
bulging side chain at this site (Figure 4E). Analysis of the pMHCs
surface can help us predict cross reactivity potential, especially
when the complexes are very similar. However, to explain all the
variation of an immune response in terms of topology and
potential is certainly impossible. Complex 2 also has differences in
topology as compared to complex 10, but it is structurally similar
to complex 6, which stimulates an intermediated response.
Differences in other points of the antigen processing and
presentation pathway (or other related pathways) will probably
be responsible for such different capacities to induce an immune
response. For instance, we could suggest that a different stability of
those complexes could be responsible for a reduction, both in
number or in time of exposure, of those complexes on the
presenting cells surface. This would reduce the probability to
establish TCR:pMHC contacts long enough to activate the
CTLs.
In conclusion, our work provides a new approach to build up
and in silico analyze pMHCs. The structural allele-specific patterns
identified can be incorporated in other immunoinformatic
approaches, in order to provide more information about peptide
affinity for specific MHC-I alleles and the immunogenicity of the
resulting complexes. The new approach to construct pMHC-I
complexes helped us understand some of the differences in the
CD8+ CVNGVCWTV-specific response and could be applied to
other studies of cross-reactivity potential among any epitopes of
interest. As previously mentioned, these peptide targets could be
further synthesized for in vitro confirmation of their immunoge-
nicity and cross-reactive potential against other targets of interest,
such as immunodominant epitopes of related viruses. Once these
features of interest are confirmed, these targets could be used in
polytope DNA vaccines, especially for heterologous prime-boost
approaches [20,21,22].
Methods
Sequence alignment
The sequences were analyzed using the Jalview multiple
alignment editor [41]. All sequences of each MHC allele were
separately aligned with the muscle algorithm. Epitope sequences
were aligned according to its physicochemical characteristics using
the software Bioedit 7.0.5.3. [42].
Construction of pMHC complexes
The pMHC complexes construction was performed through the
steps presented on Figure S8. First, we identified a PDB structure
(e.g. complex ‘‘A’’), wich includes the MHC allele of interest and
an epitope (template epitope ‘‘a’’) with the same number of amino
acids of the epitope that we want to model (e.g. ‘‘c’’ epitope).
Then, the structures of the MHC and the epitope (from ‘‘A’’
complex) were separated, saving the epitope structure in an
independent file that will be opened with the SPDBV 3.7 [43].
Using the Homology modelling menu of this software (SwissModel),
with Magic Fit, the FASTA sequence of the epitope to be modelled
(‘‘c’’ epitope) is superposed to the structure of the template epitope
‘‘a’’ (acquired from ‘‘A’’ complex). The ‘‘fit’’ structure of ‘‘c’’
epitope may have some atoms in energetically unfavorable
positions or amino acids with unfit torsions. These were corrected
running a short EM (nsteps =100) with the GROMACS 3.3.3
package [44]. At this point, we have a 3D structure related to our
epitope of interest for the first time. This structure was subjected to
a first docking (Dock1) with a MHC molecule. In this step the
MHC molecule can be those from the ‘‘A’’ complex or from
another PDB file with the same MHC allele of interest. The
epitope originally presented by this ‘‘MHC donor’’ structure
should not interfere in the analysis. It is quite important to use a
PDB file with the best possible resolution. All MHC bonds are
maintained rigid during the docking, as most of the epitopes
backbone bonds, since the epitopes main chain is already in the
suitable conformation. During the docking procedure, the epitope
side chains are flexible, which allows a great conformational
variation. At this point, a 3D model of the pMHC complex is
available, but more steps are needed to refine this model. The
resulting pMHC, with the best docking result (or the most
frequent) is subjected to a longer EM (nsteps =1000). This step is
important to adjust the MHC side chains that interact with the
new ligand, reducing unfavorable interactions. The last step is the
separation of the two components (MHC and epitope) from this
minimized complex and the use of both structures as inputs to a
second docking (Dock2) that will generate the pMHC of interest.
The second docking allows the docking program to search all over
MHC:pep Structural Patterns
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minimization over the docking results is confirmed by the
improvement of binding energies (see Table 2).
Molecular Docking
The molecular dockings were performed with AutoDock Vina
1.0.2 [31] using default values (e.g. exhaustiveness =8). For each
epitope, the same input file was used to run AutoDock Vina 20
times, generating a final population with a thousand different
conformations (20 outputs with 50 structures each). The best
conformation of each output was open together in PyMol viewer
and was analyzed according to the frequency of occurrence and
binding energy values. One of the most frequent conformations
was selected to represent the final conformation of the epitope in
the MHC-I cleft. The running time of a simulation will vary
accordingly to the computational power used, and the number of
rotatable bonds of the epitope of interest. Using our default
configuration, the running time of each docking step (20 rounds) is
about three hours in a quad core computer (using the four cores at
full capacity) and the whole process to get a pMHC complex (D1-
EM-D2) takes about 7 hours in the same scenario.
Accessible Surface Area (ASA) analyze
The ASA values were calculated in the NOC 3.01 program
[45]. The obtained values were plotted at the Microsoft Office
Excel 2007 software.
Construction of the HLA-A2-NS31073 complex and the
nine variants
The PDB structure 2V2W was used as ‘‘MHC donor’’ and the
C chain of 1T1Z structure was used as template for the HLA-
A*0201 epitopes pattern. The ten complexes were independently
constructed and analyzed as previously described (Construction of
pMHC complexes).
Analyses of topology and charges distribution
The MHC surface analyses were performed with the GRASP2
program [46], on Windows XP platform. The electrostatic
potential was calculated with a scale from 210 to +10 kiloteslas.
Images acquisition
The epitopes superposition was performed using SPDBV 3.7
[43], though the images were acquired with PyMOL 1.0 program
[47]. The pMHC top view images were generated with the
GRASP2 program [46]. Images of MHC:peptide interactions
were produced using the UCSF Chimera package from the
Resource for Biocomputing, Visualization, and Informatics at the
University of California, San Francisco (supported by NIH P41
RR-01081)[48]. All images were edited with Adobe Photoshop
CS2 v.9.0. program.
Supporting Information
Table S1 List of ligands used to identify HLA-restricted
patterns.
Found at: doi:10.1371/journal.pone.0010353.s001 (0.09 MB
DOC)
Table S2 List of H-2K
b ligands available at PDB.
Found at: doi:10.1371/journal.pone.0010353.s002 (0.04 MB
DOC)
Figure S1 Structural organization of the H-2D
b-restricted
epitopes. A: Images of HBsAg30-39 epitope (presented in Ball and
Stick_CPK) in the cleft of the H-2D
b-allele (represented as surface,
with negatively (red) and positively (blue) charged regions with a
scale from 210 to +10 kiloteslas). Partial N-terminal ending of the
epitope is hidden under MHC side chains (p2-3). Some regions of
the peptides (p6-7) protract out to the MHC cleft. B. Superposition
of 28 structures of H-2D
b-restricted epitopes (Table 1), including
side chains. It is possible to observe a higher variability in the
protracted region as compared to the N-terminal and to the
anchor sites (p5 and p9). The position of the side chains of amino
acids 1, 5, 7 and 9 are shown in both images.
Found at: doi:10.1371/journal.pone.0010353.s003 (3.57 MB
TIF)
Figure S2 Topology of H2-D
b and H2-K
b binding clefts. A:
Crystal structure of an H-2D
b allele (PDB access code 1CE6) is
depicted as Ribbon and Surface. Epitopes inside the cleft are
depicted as Sticks. Two tryptophanes of the MHC alpha-chain
(W73 and W147) almost block the cleft, forcing the peptide to pass
above them. B: Crystal structure of an H-2K
b allele (PDB access
code 1RJY) is depicted with the same configuration. The absence
of tryptophan (W73) results in a deeper cleft in this allele.
Found at: doi:10.1371/journal.pone.0010353.s004 (4.42 MB
TIF)
Figure S3 Conformational patterns of human MHC alleles. A:
Thirty-four HLA-A*0201-restricted peptides (Table S1) were
superposed using SPDBv program. Peptides sharing an A*0201-
restricted pattern are depicted in blue. Exceptions to this pattern
are depicted in cyan. Cancer-related peptides are depicted in light
pink. Epitopes 1I7R and 1I7T are depicted in red (see Discussion).
B: Superposition of five B*0801-restricted peptides. C: Superpo-
sition of five B*2705 restricted peptides. D: Superposition of three
B*3501-restricted and two B*3508-restricted peptides. In this case,
we have not enough structures to predict a pattern. Besides that,
we can see that both B*3501-restricted 9-mers (blue) presented a
similar conformation. In addition, a 10-mer peptide (APQPAPE-
NAY) presented almost the same conformation when presented by
B*3501 (orange) and B*3508 (red). A B*3508-restricted 8-mer is
also depicted (green).
Found at: doi:10.1371/journal.pone.0010353.s005 (3.56 MB TIF)
Figure S4 Exception to the H-2D
b pattern. A: The 1BZ9
epitope (red) does not have the conventional amino acid in the
anchor position (p5) and showed a significant deviation in the
main chain when compared to other epitopes. B: The side chains
of the epitope 1BZ9 (red) are in a similar conformation to other
epitopes of this allele, except in a phenylalanine at position 6 of the
epitope, which may be used as an alternative ‘‘anchor’’. Observe
the presence of an anchor amino acid in C-terminal and a hidden
Figure 4. Topology and electrostatic potential comparison among A2*0201:HCV complexes. TCR-interacting surfaces of ten different
pMHC complexes are depicted (C–L). Regions with positive (blue) and negative (red) charges are represented with a scale from 210 to +10 kiloteslas.
Sequence of presented peptide is depicted above each complex and the position of the Alanine exchange is depicted in red. Alpha-1 and Alpha-2
MHC domains are also indicated. Images A, B and C show the same pMHC, in the same position, size and orientation, although with different
representations. TCR-interacting surfaces of complexes that stimulate high levels of IFN-c production by CVNGVCWTV-specific CD8+ T-cells (J,K and L)
shared both topology and electrostatic potential. One complex that stimulates low levels of IFN-c production (G) presented differences in topology
and reduction of a negatively charged region in the TCR-interacting surface.
doi:10.1371/journal.pone.0010353.g004
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characteristics that may contribute to the presentation of this
unusual epitope.
Found at: doi:10.1371/journal.pone.0010353.s006 (2.86 MB TIF)
Figure S5 Structural pattern of H-2K
b restricted ligands. A:
Twenty-two epitopes (see Table S2) restricted to this allele were
superposed, four 9-mer (red) and 18 8-mer (blue). The H-2K
b
restricted ligands, just like those restricted to the H-2D
b allele,
presented a higher identity in the side chains of the anchor
positions than in the side chains oriented outside of the cleft. B:
Backbone superposition of the 21 ligands shows a shared
conformation among the epitopes with the same length (8-mer).
The length adjustment, in this allele, seems to be in different
positions, when compared to the H-2D
b allele.
Found at: doi:10.1371/journal.pone.0010353.s007 (2.86 MB TIF)
Figure S6 Analyze of HCV alanine exchanged peptides. The
wild type HCV derived peptide (CINGVCWTV) and nine alanine
exchanged peptides were analyzed. A: Sequences of 10 peptides
are indicated. Level of IFN-I ˆ3 production by CVNGVCWTV-
specific CD8+ T-cells, induced by each sequence, are also
represented [13]. Each bar (in black) represents the number of
the Spot Forming Units (SFU/10
4 cells) produced by each of the
peptides. Accessible Surface Area (ASA) plot of sequences that
stimulates low (B), intermediated (C) and high (D) IFN-c
production are depicted. ASA values are measured in square
angstroms. The wild type sequence (S10) was included in all plots.
Found at: doi:10.1371/journal.pone.0010353.s008 (6.62 MB TIF)
Figure S7 Flowchart of a new pMHC complex construction.
ASA values of the wild type HCV derived peptide
(CVNGVCWTV) and 28 naturally occurring NS31073-variants
were analyzed. In agreement with experimental data, the ASA
values from genotype 6 presented the same pattern of the wild type
peptide and the peptides with higher deviation from this ‘‘ASA
pattern’’ (G3_16, G3_18 and G3_20), presented the lowest levels
of IFN-c production in all ELISPOT assays (Fytili et al. 2008).
Found at: doi:10.1371/journal.pone.0010353.s009 (2.15 MB TIF)
Figure S8 Flowchart of a new pMHC complex construction.
Consider an epitope ‘‘C’’ whose structure in the context of a given
MHC allele was not determined. A search at PDB is performed,
looking for a PDB file containing the allele of interest presenting
an epitope with the same length of the ‘‘c’’ epitope. In this
example, we found the ‘‘A’’ complex. Using the SPDBV program,
it was observed that the amino acid sequence of the epitope ‘‘c’’ is
‘‘Fit’’ on the 3D structure of the epitope present at the ‘‘A’’
complex. The generated structure of the epitope ‘‘c’’ is submitted
to an energy minimization (EM), and is used as input for the
docking with an ‘‘MHC donor’’ structure (B). In order to adjust
the MHC to this new epitope, an EM of the complex ‘‘D’’ is
performed. After minimization, epitope and MHC are separated
and used as inputs to a second docking, which will generate the
desired pMHC complex (E). For more information see methods.
Found at: doi:10.1371/journal.pone.0010353.s010 (2.86 MB TIF)
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